PMID: 11321189Apr 26, 2001Paper

The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis--preliminary results

Multiple Sclerosis : Clinical and Laboratory Research
N A LosseffA J Thompson

Abstract

As short-term MRI studies are increasingly being used to monitor disease activity in multiple sclerosis (MS) it is vital to establish if short-term MRI activity is predictive of long term clinical outcome. We followed up after 5 years a group of 10 benign (relapsing-remitting MS with a disease duration > 10 years and EDSS < or = 3) and 10 early relapsing-remitting patients who previously had monthly serial MRI scans for 6 months. In the early relapsing-remitting group median EDSS at entry to the initial serial study was three and in the benign group 2.5. At 5-year follow up, five of these 20 patients had developed a definite deterioration in EDSS. The median number of new enhancing lesions detected originally in the group that had deteriorated was 11 (7-17) compared to 0 (0-5) new enhancing lesions, for those who had not deteriorated (P < 0.05). There was a trend towards a higher baseline T2 lesion load in the group with a definite change in EDSS but this was not significant This study suggests that short-term measurement of the number of gadolinium enhancing lesions may predict long term outcome in relapsing-remitting MS.

References

Feb 1, 1991·Neurology·D E Goodkin
Mar 10, 1990·BMJ : British Medical Journal·A J ThompsonW I McDonald
Sep 1, 1994·Journal of Neurology, Neurosurgery, and Psychiatry·D KiddW I McDonald
Dec 1, 1996·Brain : a Journal of Neurology·N A LosseffA J Thompson
Apr 29, 1998·Brain : a Journal of Neurology·J I O'RiordanD H Miller

❮ Previous
Next ❯

Citations

Mar 25, 2009·Journal of Neurology·Michael HutchinsonUNKNOWN AFFIRM and SENTINEL Investigators
May 2, 2013·Journal of Neurology·Jeffrey A CohenGordon Francis
Jun 23, 2012·Multiple Sclerosis : Clinical and Laboratory Research·Aaron E MillerUNKNOWN Teriflunomide Multiple Sclerosis Trial Group
Dec 31, 2005·Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging·Robert Zivadinov, Thomas P Leist
Jan 1, 2012·Multiple Sclerosis and Related Disorders·Kottil RammohanNuwan Kurukulasuriya
Dec 22, 2015·Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging·Lael Anne StoneHenry McFarland
Apr 16, 2011·Human Brain Mapping·Mathias WahlUlf Ziemann
Jul 17, 2013·Therapeutic Advances in Neurological Disorders·Jan-Mendelt Tillema, Istvan Pirko
Sep 1, 2011·Multiple Sclerosis : Clinical and Laboratory Research·Ludwig KapposGilmore N O'Neill
Feb 26, 2003·Neurology·Francois CottonCharles R G Guttmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.